Year: 2022

POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings

Written by Customer Service on November 14, 2022. Posted in Earnings Releases And Operating Results.

INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended September 30, 2022, and provided an update on business highlights, including the announcement of a strategic collaboration and exclusive license agreements with Lantheus Holdings Inc. (NASDAQ: LNTH) for the commercialization of PNT2002 & PNT2003. Upon consummation of the agreements, in exchange for the exclusive worldwide rights1, Lantheus will pay a total of $260 million in upfront payments between the two agreements to POINT, with the potential for additional milestone payments of approximately $1.8 billion between the two products based on...

Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update

Written by Customer Service on November 14, 2022. Posted in Earnings Releases And Operating Results.

On track to submit IND filings in U.S. and China for GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the fourth quarter 2022 First clinical data from ongoing investigator-initiated trial (IIT) evaluating GC012F in newly-diagnosed multiple myeloma (NDMM) patients to be presented as oral session at 64th American Society of Hematology Annual Meeting and Exposition (ASH 2022) Continued patient enrollment and follow-up in the ongoing IIT evaluating GC012F in relapsed/refractory B-Cell non-Hodgkin lymphoma (r/r B-NHL) Dosed first patient in registrational Phase 2 clinical trial evaluating GC007g for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) Dosed first patients in IIT evaluating GC503 for the treatment of mesothelin-positive solid tumors Well-funded with cash runway for...

Itafos Reports Record Q3 and 9M 2022 Results, Confirms Full-Year 2022 Guidance

Written by Customer Service on November 14, 2022. Posted in Earnings Releases And Operating Results.

Q3 2022 Key Highlightsrevenues of $153.2 million adjusted EBITDA of $50.7 million(1) net income of $8.1 million basic earnings of C$0.06/share free cash flow of $53.6 million(1)9M 2022 Key Highlightsrevenues of $458.0 million adjusted EBITDA of $174.6 million net income of $85.4 million basic earnings of C$0.58/share free cash flow of $149.2 millionSeptember 30, 2022 Key Highlightstrailing 12 months adjusted EBITDA of $222.6 million(1) net debt of $117.7 million(1) net leverage ratio of 0.5x(1)Maintained FY 2022 Guidanceadjusted EBITDA guidance of $210-230 million net income guidance of $100-105 million basic earnings guidance of C$0.69-0.72/share maintenance capex guidance of $18-22 million(1) growth capex guidance of $18-21 million(1) free cash flow guidance of $150-165 millionCEO Commentary “We are pleased to report...

Evaxion Announces Third Quarter 2022 Financial Results and Business Update

Written by Customer Service on November 14, 2022. Posted in Earnings Releases And Operating Results.

Per Norlén, M.D., PhD. joined Evaxion as Chief Executive Officer in OctoberEnrollment of the first patient in our global Phase 2b clinical trial of EVX-01Increased strategic focus on clinical lead oncology assets and partneringCash and cash equivalents of $17.9 million sufficient to fund operations into mid-2023COPENHAGEN, Denmark, Nov. 14, 2022 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today its third quarter 2022 financial results and provided an operational and business update. Per Norlén, CEO of Evaxion, said: “Evaxion continues to advance its drug development pipeline, reaching an important milestone in the third quarter with the enrollment of the first patient in...

Gilat Presents Strong Growth and Results for Third Quarter 2022

Written by Customer Service on November 14, 2022. Posted in Earnings Releases And Operating Results.

Revenue of $60.4 million, up 21% year-over-year, GAAP operating income of $3.4 million versus $0.8 million in Q3 last year, and adjusted EBITDA of $7.3 million, up 88% year-over-year PETAH TIKVA, Israel, Nov. 14, 2022 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial HighlightsRevenues of $60.4 million,up 21% compared with $49.8 million in Q3 last year; GAAP operating income of $3.4 million versus $0.8 million in Q3 last year; Non-GAAP operating income of $4.4 million versus $1.3 million in Q3 last year; GAAP net income of $2.1 million versus breakeven in Q3 last year; Non-GAAP net income of $3 million versus $0.6 million...

Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

Written by Customer Service on November 14, 2022. Posted in Earnings Releases And Operating Results.

– Significant and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of 20 mg/kg VRDN-001; generally consistent with 10mg/kg results at week 6 – – Global Phase 3 THRIVE clinical program initiated – – Ended 3Q 2022 with cash, cash equivalents, and short-term investments of $431M providing cash runway into the second half of 2025 – – Conference call today at 8:00 a.m. ET – WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced financial results for the third quarter ending September 30, 2022 and provided corporate updates. Earlier today in a separate news release, the Company...

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Written by Customer Service on November 14, 2022. Posted in Public Companies.

– Significant and rapid improvement in both signs and symptoms of TED after two infusions of 20 mg/kg VRDN-001, generally consistent with 10 mg/kg results at week 6 – – Global Phase 3 THRIVE clinical program initiated – – Across all VRDN-001 treated patients to date: 75% were proptosis responders, 75% were overall responders, 58% achieved a Clinical Activity Score (CAS) of 0 or 1, and 75% had complete resolution of their diplopia – – Safety profile favorable at 20 mg/kg dose, with no reported SAEs, no drug-related hyperglycemia, no hearing impairment, and no infusion reactions – – Low volume SC programs on track for proof-of-concept data in 2H23; final Phase 1 data for VRDN-002 demonstrates half-life up to 43 days – – Company well capitalized with cash, cash equivalents,...

Dentsply Sirona Reports Third Quarter 2022 Results

Written by Customer Service on November 14, 2022. Posted in Earnings Releases And Operating Results.

Net sales decreased (8.9%) to $947 million, organic sales decreased (0.7%) GAAP EPS loss of ($5.01), adjusted EPS of $0.41 down (31.5%) year-over-year Operating cash flow of $109 million Updated FY22 outlook: organic sales decline of ~(2%); adj. EPS range of $1.90 to $2.00CHARLOTTE, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced its financial results for the third quarter of 2022. Third quarter net sales of $947 million decreased (8.9%), compared to $1,040 million in the third quarter of 2021. Foreign currency translation negatively impacted sales by (8.2%). Net loss for the third quarter of 2022 was ($1,077) million, or ($5.01) loss per diluted share, compared to $84 million, or $0.38 per diluted share in the third quarter of 2021....

The Keg Royalties Income Fund announces November 2022 cash distribution

Written by Customer Service on November 14, 2022. Posted in Dividend Reports And Estimates.

VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) today announced that its November 2022 distribution of $0.0946 per unit has been declared and is payable to unitholders of record as of November 21, 2022. The November 2022 distribution will be paid on November 30, 2022. The Fund is a limited purpose, open-ended trust established under the laws of the Province of Ontario that, through The Keg Rights Limited Partnership, a subsidiary of the Fund, owns certain trademarks and other related intellectual property used by Keg Restaurants Ltd. (“KRL”). In exchange for use of those trademarks, KRL pays the Fund a royalty of 4% of gross sales of Keg restaurants included in the royalty pool. Vancouver-based KRL is the leading operator and franchisor of steakhouse restaurants...

Caisse Française de Financement Local: Report on asset quality as of September 30, 2022

Written by Customer Service on November 14, 2022. Posted in Public Companies.

Issy-les-Moulineaux, November 14, 2022 REPORT ON ASSET QUALITY AS OF SEPTEMBER 30, 2022 In accordance with the regulatory requirements in force, Caisse Française de Financement Local announces that the French version of the report on asset quality as of September 30, 2022 was filed with the Autorité de contrôle prudentiel et de résolution (ACPR) on November 14, 2022 and that it can be obtained from its website: https://caissefrancaisedefinancementlocal.fr/investisseurs/publications/ (heading: Rapport sur la qualité des actifs). The English version of the report on asset quality as of September 30, 2022 can be obtained from its website: https://caissefrancaisedefinancementlocal.fr/en/investor/publications/ (heading: Report on asset quality).AttachmentCAFFILCommuniqueGB

Year: 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals